Head-to-head evidence
HRS-1301 vs Recaticimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
HRS-1301
Developed by Jiangsu Hengrui Pharmaceuticals and partners
NCT06857253 · Phase 1 · completed
This is a real randomized, blinded, placebo-controlled study, which is a solid design, but its primary measure is adverse-event safety monitoring rather than a cholesterol or cardiovascular outcome, and results have not been posted yet.
Recaticimab
Developed by Jiangsu Hengrui Pharmaceuticals
NCT04849000 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 709 participants, using percentage change in LDL cholesterol as the primary measure. The sponsor reports statistically significant LDL reductions of 45 to 53 percentage points versus placebo across all three dosing regimens.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-1301's landscape · Recaticimab's landscape